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GI DISEASES/DISORDERS
GI DISEASES/DISORDERS—Health Policy Studies
PGI11
RETROSPECTIVE ANALYSIS OF A PRIOR AUTHORIZATION
PROGRAM USING COX-2 INHIBITORS IN A MANAGED CARE
POPULATION
Barlev A1,Yu W2, Johnson K1
1University of Southern California, Los Angeles, CA, USA; 2WellPoint
Pharmacy Management, West Hills, CA, USA
OBJECTIVES: This study examines the patient level factors that
play role in initiating the process of prior authorization, and
evaluates whether prior authorization (PA) process has an effect
on future gastrointestinal (GI) outcomes (e.g. bleeding, peptic
ulcer disease (PUD)) in managed care population. METHODS:
Patients who encountered a PA system edit for Cox-2 inhibitors
during January 1, 2001 to July 31, 2002 were followed up for
1 year post rejection date. Patients were stratiﬁed to 2 groups;
1) initiated the process of PA, 2) never initiated the process of
PA. Using multivariate logistic regression, signiﬁcant covariates
in predicting future GI bleed or PUD, and applying for PA were
identiﬁed. Charlson Comorbidity Index (CCI) was calculated for
each patient and used in the regression analysis. RESULTS:
Those who initiated the PA process were signiﬁcantly older, had
higher CCI, higher total medical and pharmacy costs, and more
GI events than those who never applied for a PA. Signiﬁcant
covariates in predicting future GI bleed were aged £65, previous
GI bleed or PUD, and higher CCI. In addition to gender similar
covariates also predicted future PUD where females were at
higher risk of having a PUD. Whether prior authorization
process was initiated or not was not a signiﬁcant factor in pre-
dicting future GI event. Patients who are females or age £65,
with osteoarthritis, rheumatoid arthritis, previous ulcer or GI
bleed event, or high CCI score were more likely to apply for PA.
CONCLUSION: PA process appears to select high risk patients
to receive Cox-2 inhibitors. Patients who did not apply for PA
appear to have similar adjusted future GI event rate than those
who applied.
GI DISEASES/DISORDERS
GI DISEASES/DISORDERS—Methods
PGI12
EVALUATING THE GERD SYMPTOM AND MEDICATION
QUESTIONNAIRE (GERD-SMQ) IN A CLINICAL TRIAL
Howell JB1, Reyes EB2, Dylan M2,Wade SW2, Dodd SL1,
DeLemos BP1
1Janssen Pharmaceutica, Inc,Titusville, NJ, USA; 2Zynx Health, Beverly
Hills, CA, USA
OBJECTIVES: Assess the construct validity of the GERD-SMQ
in relation to esophagitis grade severity, symptom severity, and
quality of life within a clinical trial. METHODS: The GERD-
SMQ was administered to 1722 subjects participating in a mul-
ticenter, randomized double-blind clinical trial. Subjects had a
history of erosive esophagitis based on an endoscopy (EGD) per-
formed at study entry or a previous EGD within ﬁve years. The
Modiﬁed Hetzel-Dent Grading Scale was used to determine
esophagitis grade scores. A 4-point Likert scale was used to
assess GERD symptoms and the Gastroesophageal Reﬂux
Disease Symptom Assessment Scale (GSAS) distress domain
assessed quality of life (QOL). Logistic regression, using the
GERD-SMQ score (based on previous validation using the heart-
burn + regurgitation + medication subscores) as the independent
variable, was performed to test the GERD-SMQ’s degree of asso-
ciation with esophagitis grade and GERD symptoms. ANOVA
techniques, using QOL as the independent variable, were
employed to test the GERD-SMQ’s degree of association with
QOL scores. RESULTS: Results of ordinal logistic regression
univariate analyses using esophagitis grade score as the depen-
dent variable showed that as GERD-SMQ score increased by one
unit, the odds of having more severe symptoms also increased
signiﬁcantly (OR 1.04, p < 0.05). Using screening symptoms
scores as the dependent variable, the odds of having more severe
symptoms signiﬁcantly increased with observed increases in
GERD-SMQ scores (OR 1.22, p < 0.0001). Analysis of variance
results showed that for every one unit increase in the GSAS 
distress score, the GERD-SMQ score signiﬁcantly increased 
by a factor of 2.39 (p < 0.0001). CONCLUSIONS: Signiﬁcant
relationships exist between the GERD-SMQ score, speciﬁc 
symptoms and clinical severity markers demonstrating that 
the GERD-SMQ is valuable in the clinical trial setting. Further
evaluation of the GERD-SMQ is warranted to determine the 
use of this questionnaire in patients with symptoms of GERD
with or without erosive esophagitis.
INFECTIONS
INFECTIONS—Clinical Outcomes Studies
PIN1
OUTCOMES OF AN INTERACTIVE VOICE RESPONSE (IVR)
REMINDER SYSTEM TO PROMOTE MANAGED CARE
ORGANIZATION (MCO) MEMBERS’ ATTAINMENT OF
INFLUENZA IMMUNIZATION
Sikirica V1, Crawford A1, Goldfarb N1, Nash D1, Popiel R2, Patel M2,
Wang C2, Chu J2
1Department of Health Policy, Jefferson Medical College, Philadelphia,
PA, USA; 2Horizon Blue Cross Blue Shield of New Jersey, Newark,
NJ, USA
OBJECTIVES: To determine if an IVR intervention was associ-
ated with attainment of the preventive service of inﬂuenza immu-
nization for older adults. METHODS: A MCO in the Eastern
U.S. identiﬁed a cohort of members (n = 22,501) age 65 and over
as of January 1st, 2002 who were eligible for inﬂuenza immu-
nization based on the Health Plan Employer Data and Informa-
tion Set (HEDIS) speciﬁcations. The intervention consisted of
telephone calls with IVR system prompts to remind patients to
get immunized. Rates of adherence were compared based on
whether members received a reminder. Calls were classiﬁed as
reminders if the targeted member was contacted directly, or
called in to the system after having heard the reminder, or if the
reminder was left with another household member or on an
answering machine. Calls were classiﬁed as non-reminders if the
member hung-up, no connection was made, or if the targeted
member or another household member declined the intervention.
The telephone intervention began October 10th, 2002 and ended
January 21st, 2003. Claims data for immunizations were evalu-
ated from October 10th, 2002 to March 31st, 2003. Multivari-
ate logistic regressions evaluated associations between the
intervention and odds of getting the inﬂuenza immunization,
controlling for age group and gender. RESULTS: Of members
receiving the IVR reminder 6.9% got inﬂuenza immunizations,
while 3.2% of members not receiving the reminder got immu-
nizations (p < 0.0001). Logistic regression revealed signiﬁcant
associations between the IVR reminder and the likelihood of
receiving the immunization, controlling for age group and gender
(p < 0.0001). Neither age group nor gender signiﬁcantly affected
the odds of getting an immunization. Members who received a
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reminder were 2.15 times (95% CI = 1.73 to 2.61) more likely
to have an inﬂuenza immunization. CONCLUSIONS: Although
inﬂuenza immunization rates remain low, IVR reminders
produce higher rates of inﬂuenza immunizations and increase
patient adherence in older adults.
PIN2
RETREATMENT RATES OF ACUTE OTITIS MEDIA IN PATIENTS
WITH TYMPANOSTOMY TUBES WITHIN THE LOUISIANA
MEDICAID PROGRAM
Blake S1, Waycaster C2, Kothari S1, Myers E1, Humble L1, Bollu VK1
1ULM School of Pharmacy, Monroe, LA, USA; 2Alcon Labs Inc, Fort
Worth,TX, USA
OBJECTIVES: Retreatment of acute infections can often be high
thereby increasing treatment costs. This study examined the
retreatment rates of acute otitis media in patients with tympa-
nostomy tubes (AOMT) within the Louisiana Medicaid popula-
tion. METHODS: Louisiana Medicaid claims data for
2000–2002 were retrospectively reviewed for episodes of
AOMT. Tympanostomy tube (t-tube) patients were identiﬁed
using CPT codes from an index period of January 1, 2000
through June 30, 2000. AOMT patients were followed for 24
months from their respective index dates. Episodes of AOMT
were then identiﬁed from the t-tube sample group using ICD-
9-CM codes. An episode started with the ﬁrst antibiotic claim
between one day before or two days after an ICD-9-CM code
for AOMT and ended 21 days later. Retreatment was deﬁned as
the presence of another antibiotic claim between days 3 and days
21 of an episode of care. Only antibiotics commonly used in the
treatment of AOMT were considered in the retreatment analy-
sis. Retreatment rates were calculated on an overall (per episode)
basis and by antibiotic. RESULTS: There were 5934 episodes of
AOMT care identiﬁed within the dataset of which 1381 required
retreatment resulting in an overall retreatment rate of approxi-
mately 23%. Some of the antibiotics commonly prescribed in the
treatment of AOMT are presented in rank order relative to their
retreatment rates: ciproﬂoxacin HCL and hydrocortisone (12%),
cephalexin (17%), oﬂoxacin (26%), amoxicillin (28%), amoxi-
cillin potassium clavulanate (32%), sulfamethoxazole trimetho-
prim (32%), azithromycin (32%), clarithromycin (33%),
cefdinir (33%), and cefprozil (36%). CONCLUSIONS: The
retreatment rate of AOMT in the Louisiana Medicaid popula-
tion was high with approximately 1 out of 4 episodes requiring
retreatment. Retreatment rates also varied considerably between
antibiotic therapies. Careful consideration of AOMT antibiotic
therapy by clinicians may reduce retreatment rates thereby low-
ering the associated cost of AOMT treatment in the Louisiana
Medicaid program.
PIN3
OUTCOMES FOLLOWING THE USE OF AZITHROMYCIN OR
CLARITHROMYCIN FOR RESPIRATORY TRACT INFECTIONS
IN A MEDICAID POPULATION
Boulanger L1, Harnett J2, Dixon D1, Menzin J1,Wilson J2
1Boston Health Economics, Inc, Waltham, MA, USA; 2Pﬁzer, Inc, New
York, NY, USA
OBJECTIVE: To better understand the consequences of branded
macrolide therapy, we assessed rates of re-treatment following
the use of azithromycin or clarithromycin among outpatients
diagnosed with common respiratory-tract infections in the 
California Medicaid (“Medi-Cal”) program. METHODS: We
employed a retrospective cohort design using administrative
claims data for a 20% random sample of California Medicaid
recipients. We selected outpatients diagnosed with common
upper or lower respiratory-tract infections, including acute otitis
media, acute pharyngitis, acute sinusitis, chronic bronchitis, or
community-acquired pneumonia during an ofﬁce visit between
February 1, 1997 and May 31, 2002. Patients were prescribed
either azithromycin or clarithromycin as treatment following
diagnosis. The main study outcome was the ﬁlling of another
prescription for an antibiotic (i.e., “retreatment”) within 30 days
following receipt of branded macrolide therapy. For each infec-
tion type, logistic regression was used to estimate the rate of
retreatment for the two initial macrolides, adjusting for age.
RESULTS: We identiﬁed 6196 patients diagnosed with acute
otitis media, 3794 with community-acquired pneumonia, 2716
diagnosed with pharyngitis, 1354 with chronic bronchitis, and
1162 with sinusitis who received one of the two macrolides of
interest. Sixteen (acute otitis media) to 20% (sinusitis) of patients
failed treatment with their initial macrolide. Relative to clar-
ithromycin, azithromycin was associated with a signiﬁcantly
lower retreatment rate when used in patients with acute otitis
media (OR: 0.63; 95% CI: 0.50 to 0.80; P < 0.0001) or chronic
bronchitis (0.70; 0.50 to 0.98; P = 0.039). The likelihood of
retreatment (azithromycin relative to clarithromycin) did not
differ for patients with pharyngitis (0.96; 0.74 to 1.26; P =
0.783), sinusitis (1.03; 0.75 to 1.42; P = 0.842), or community-
acquired pneumonia (0.93; 0.77 to 1.13; P = 0.450). CON-
CLUSIONS: Compared to clarithromycin, azithromycin is
associated with a lower retreatment rate when used for acute
otitis media or chronic bronchitis in this Medicaid population.
PIN4
EXAMINATION OF HEPATITIS C IN THE LOUISIANA
MEDICAID POPULATION
Dalal A, Blake SG
University of Louisiana at Monroe, Monroe, LA, USA
OBJECTIVE: The purpose of this study was to examine the 
epidemiology of Hepatitis C (HCV) in the Louisiana Medicaid
population. HCV is estimated to have infected 170 million
people worldwide. In many countries, it is the most common
cause of chronic liver disease and is the most common indica-
tion for liver transplantation. Progression and complications of
the disease may lead to cirrhosis, liver failure, and hepatocellu-
lar carcinoma (HCC). HCV affects nearly 4 million people in the
U.S. HCV causes an estimated 10,000 to 12,000 deaths annu-
ally in the U.S. Approximately 70% of these people develop
chronic hepatitis and 20% progress to cirrhosis predisposing
them to HCC. METHODS: This study is a retrospective sec-
ondary database claims analysis. Medicaid recipients were fol-
lowed longitudinally for the years 1998, 1999, and 2000, which
consequently constitute the study period for this research. Recip-
ients were included in one of two groups based on their diag-
nosis: Infected (having HCV) and at-risk (having a diagnosis of
hemophilia, cocaine addiction, drug abuse, cirrhosis, hepatitis B,
and HIV or received hemodialysis). Only recipients who were
continuously eligible throughout the 3-year study period were
included in the study. RESULTS: The prevalence of HCV in the
LA Medicaid population during the study period was 7.08 per
1000. Among the at-risk population, the recipients with a diag-
nosis hemophilia or drug abuse had the highest prevalence. There
were 18,286 recipients in the at-risk group while 2128 recipients
were classiﬁed in the infected group. The infected group con-
sisted of 1151 females (54%) and racial breakdown showed that
1183 (55%) African Americans had HCV. Similar results were
obtained when at-risk groups were analyzed. CONCLUSIONS:
Most frequently occurring comorbidities in the infected popula-
tion, were asthma, chest pain, urinary tract infection and bron-
chitis. About 30 % of the recipients in the at-risk group had been
tested for HCV.
